<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31888078</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Dec</Month><Day>26</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>TDP-43-Mediated Toxicity in HEK293T Cells: A Fast and Reproducible Protocol To Be Employed in the Search of New Therapeutic Options against Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">68</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells9010068</ELocationID><Abstract><AbstractText>Cytoplasmic TDP-43 aggregates are a hallmark of amyotrophic lateral sclerosis (ALS). Today, only two drugs are available for ALS treatment, and their modest effect prompts researchers to search for new therapeutic options. TDP-43 represents one of the most promising targets for therapeutic intervention, but reliable and reproducible in vitro protocols for TDP-43-mediated toxicity are lacking. Here, we used HEK293T cells transfected with increasing concentrations of TDP-43-expressing plasmid to evaluate different parameters of toxicity and alterations in cellular metabolism. Overexpression of TDP-43 induced aggregates occurrence followed by the detection of 25- and 35-kDa forms of TDP-43. TDP-43 overexpression decreased cell viability and increased cells arrested at G2/M phase and nuclear fragmentation. Analysis of the energetic metabolism showed a tendency to decrease oxidative phosphorylation and increase glycolysis, but no statistical differences were observed. Metabolomics revealed alterations in different metabolites (mainly sphingolipids and glycerophospholipids) in cells overexpressing TDP-43. Our data reveal the main role of TDP-43 aggregation in cellular death and highlight novel insight into the mechanism of cellular toxicity induced by TDP-43. Here, we provide a simple, sensitive, and reliable protocol in a human-derived cell line to be used in high-throughput screenings of potential therapeutic molecules for ALS treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lanznaster</LastName><ForeName>D&#xe9;bora</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourgeais</LastName><ForeName>J&#xe9;r&#xf4;me</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CNRS ERL7001, EA 7501 GICC, University of Tours, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruno</LastName><ForeName>Clement</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CHU de Tours, Service de Biochimie et Biologie Mol&#xe9;culaire, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hergesheimer</LastName><ForeName>Rudolf C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thepault</LastName><ForeName>Rose-Anne</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7960-8139</Identifier><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Biochimie et Biologie Mol&#xe9;culaire, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andres</LastName><ForeName>Christian R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Biochimie et Biologie Mol&#xe9;culaire, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herault</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-7419-1124</Identifier><AffiliationInfo><Affiliation>CNRS ERL7001, EA 7501 GICC, University of Tours, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Biochimie et Biologie Mol&#xe9;culaire, 37000 Tours, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>LabEx MAbImprove ANR-10-LABX-53-01</GrantID><Agency>Minist&#xe8;re de l'Enseignement Sup&#xe9;rieur et de la Recherche</Agency><Country/></Grant><Grant><GrantID>ARD2020 Biom&#xe9;dicaments - INTRABALS</GrantID><Agency>Conseil R&#xe9;gional du Centre-Val de Loire</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055442" MajorTopicYN="N">Metabolome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="Y">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="Y">Protein Aggregation, Pathological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">aggregation</Keyword><Keyword MajorTopicYN="N">apoptosis</Keyword><Keyword MajorTopicYN="N">cellular death</Keyword><Keyword MajorTopicYN="N">metabolomics</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31888078</ArticleId><ArticleId IdType="pmc">PMC7016571</ArticleId><ArticleId IdType="doi">10.3390/cells9010068</ArticleId><ArticleId IdType="pii">cells9010068</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buratti E., Baralle F.E. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J. Biol. Chem. 2001;276:36337&#x2013;36343. doi: 10.1074/jbc.M104236200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M104236200</ArticleId><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M., Lagier-Tourenne C., Hutt K.R., Huelga S.C., Moran J., Liang T.Y., Ling S.C., Sun E., Wancewicz E., Mazur C., et al. Long pre-MRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 2011;14:459&#x2013;468. doi: 10.1038/nn.2779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer R.C., Chami A.A., de Assis D.R., Vourc&#x2019;h P., Andres C.R., Corcia P., Lanznaster D., Blasco H. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: A resolution in sight? Brain J. Neurol. 2019;142:1176&#x2013;1194. doi: 10.1093/brain/awz078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz078</ArticleId><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Baralle M., Buratti E., Baralle F.E. The role of TDP-43 in the pathogenesis of ALS and FTLD. Biochem. Soc. Trans. 2013;41:1536&#x2013;1540. doi: 10.1042/BST20130186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20130186</ArticleId><ArticleId IdType="pubmed">24256250</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A., Bharathi V., Sivalingam V., Girdhar A., Patel B.K. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 2019;12:25. doi: 10.3389/fnmol.2019.00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowley L.C., Chojnowski G., Waterhouse N.J. Measuring the DNA content of cells in apoptosis and at different cell-cycle stages by propidium iodide staining and flow cytometry. Cold Spring Harb. Protoc. 2016;2016:10. doi: 10.1101/pdb.prot087247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/pdb.prot087247</ArticleId><ArticleId IdType="pubmed">27698234</ArticleId></ArticleIdList></Reference><Reference><Citation>Patin F., Baranek T., Vourc&#x2019;h P., Nadal-Desbarats L., Goossens J.F., Marouillat S., Dessein A.F., Descat A., Hounoum B.M., Bruno C., et al. Combined metabolomics and transcriptomics approaches to assess the IL-6 blockade as a therapeutic of ALS: Deleterious alteration of lipid metabolism. Neurother. J. Am. Soc. Exp. NeuroTher. 2016;13:905&#x2013;917. doi: 10.1007/s13311-016-0461-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0461-3</ArticleId><ArticleId IdType="pmc">PMC5081117</ArticleId><ArticleId IdType="pubmed">27444617</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskelinen M.H., Kivipelto M. Caffeine as a protective factor in dementia and alzheimer&#x2019;s disease. J. Alzheimers Dis. JAD. 2010;20:S167&#x2013;S174. doi: 10.3233/JAD-2010-1404.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-1404</ArticleId><ArticleId IdType="pubmed">20182054</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia J., Wishart D.S. Using metaboanalyst 3.0 for comprehensive metabolomics data analysis. Curr. Protoc. Bioinform. 2016;55:14.10.1&#x2013;14.10.91. doi: 10.1002/cpbi.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpbi.11</ArticleId><ArticleId IdType="pubmed">27603023</ArticleId></ArticleIdList></Reference><Reference><Citation>Madji Hounoum B., Blasco H., Coque E., Vourc&#x2019;h P., Emond P., Corcia P., Andres C.R., Raoul C., Mavel S. The metabolic disturbances of motoneurons exposed to glutamate. Mol. Neurobiol. 2018;55:7669&#x2013;7676. doi: 10.1007/s12035-018-0945-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0945-8</ArticleId><ArticleId IdType="pubmed">29435916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganini D., Leinisch F., Kumar A., Jiang J., Tokar E.J., Malone C.C., Petrovich R.M., Mason R.P. Fluorescent proteins such as eGFP lead to catalytic oxidative stress in cells. Redox Biol. 2017;12:462&#x2013;468. doi: 10.1016/j.redox.2017.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2017.03.002</ArticleId><ArticleId IdType="pmc">PMC5362137</ArticleId><ArticleId IdType="pubmed">28334681</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansari A.M., Ahmed A.K., Matsangos A.E., Lay F., Born L.J., Marti G., Harmon J.W., Sun Z. Cellular GFP toxicity and immunogenicity: Potential confounders in In Vivo cell tracking experiments. Stem Cell. Rev. Rep. 2016;12:553&#x2013;559. doi: 10.1007/s12015-016-9670-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-016-9670-8</ArticleId><ArticleId IdType="pmc">PMC5050239</ArticleId><ArticleId IdType="pubmed">27435468</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V., Phaneuf D., Dupre N., Petri S., Strong M., Kriz J., Julien J.P. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. J. Exp. Med. 2011;208:2429&#x2013;2447. doi: 10.1084/jem.20111313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111313</ArticleId><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibiger C., Deisel J., Aufschnaiter A., Ambros S., Tereshchenko M., Verheijen B.M., Buttner S., Braun R.J. TDP-43 controls lysosomal pathways thereby determining its own clearance and cytotoxicity. Hum. Mol. Genet. 2018;27:1593&#x2013;1607. doi: 10.1093/hmg/ddy066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy066</ArticleId><ArticleId IdType="pubmed">29474575</ArticleId></ArticleIdList></Reference><Reference><Citation>Budini M., Buratti E., Morselli E., Criollo A. Autophagy and its impact on neurodegenerative diseases: New roles for TDP-43 and C9orf72. Front. Mol. Neurosci. 2017;10:170. doi: 10.3389/fnmol.2017.00170.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00170</ArticleId><ArticleId IdType="pmc">PMC5447761</ArticleId><ArticleId IdType="pubmed">28611593</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella R., Fani G., Capitini C., Rusmini P., Poletti A., Cecchi C., Chiti F. Quantitative assessment of the degradation of aggregated TDP-43 mediated by the ubiquitin proteasome system and macroautophagy. FASEB J. 2017;31:5609&#x2013;5624. doi: 10.1096/fj.201700292RR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201700292RR</ArticleId><ArticleId IdType="pubmed">28842427</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C.C., Bose J.K., Majumder P., Lee K.H., Huang J.T., Huang J.K., Shen C.K. Metabolism and mis-metabolism of the neuropathological signature protein TDP-43. J. Cell Sci. 2014;127:3024&#x2013;3038. doi: 10.1242/jcs.136150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.136150</ArticleId><ArticleId IdType="pubmed">24860144</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Yokoshi M., Okada H., Kawahara Y. The cleavage pattern of TDP-43 determines its rate of clearance and cytotoxicity. Nat. Commun. 2015;6:6183. doi: 10.1038/ncomms7183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7183</ArticleId><ArticleId IdType="pubmed">25630387</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita M., Nonaka T., Hirai S., Miwa A., Okado H., Arai T., Hosokawa M., Akiyama H., Hasegawa M. Distinct pathways leading to TDP-43-induced cellular dysfunctions. Hum. Mol. Genet. 2014;23:4345&#x2013;4356. doi: 10.1093/hmg/ddu152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu152</ArticleId><ArticleId IdType="pubmed">24698978</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim E.K., Choi E.J. Compromised MAPK signaling in human diseases: An update. Arch. Toxicol. 2015;89:867&#x2013;882. doi: 10.1007/s00204-015-1472-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00204-015-1472-2</ArticleId><ArticleId IdType="pubmed">25690731</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortarolo M., Veglianese P., Calvaresi N., Botturi A., Rossi C., Giorgini A., Migheli A., Bendotti C. Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol. Cell. Neurosci. 2003;23:180&#x2013;192. doi: 10.1016/S1044-7431(03)00022-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1044-7431(03)00022-8</ArticleId><ArticleId IdType="pubmed">12812752</ArticleId></ArticleIdList></Reference><Reference><Citation>Wengenack T.M., Holasek S.S., Montano C.M., Gregor D., Curran G.L., Poduslo J.F. Activation of programmed cell death markers in ventral horn motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in a transgenic mouse model. Brain Res. 2004;1027:73&#x2013;86. doi: 10.1016/j.brainres.2004.08.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2004.08.054</ArticleId><ArticleId IdType="pubmed">15494159</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Deng J., Dong J., Liu J., Bigio E.H., Mesulam M., Wang T., Sun L., Wang L., Lee A.Y., et al. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. PLoS Genet. 2019;15:e1007947. doi: 10.1371/journal.pgen.1007947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1007947</ArticleId><ArticleId IdType="pmc">PMC6524796</ArticleId><ArticleId IdType="pubmed">31100073</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam M., Jara J.H., Kocak N., Rylaarsdam L.E., Kim K.D., Bigio E.H., Hande Ozdinler P. Mitochondria, ER, and nuclear membrane defects reveal early mechanisms for upper motor neuron vulnerability with respect to TDP-43 pathology. Acta Neuropathol. 2019;137:47&#x2013;69. doi: 10.1007/s00401-018-1934-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1934-8</ArticleId><ArticleId IdType="pmc">PMC6339587</ArticleId><ArticleId IdType="pubmed">30450515</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis S.A., Itaman S., Khalid-Janney C.M., Sherard J.A., Dowell J.A., Cairns N.J., Gitcho M.A. TDP-43 interacts with mitochondrial proteins critical for mitophagy and mitochondrial dynamics. Neurosci. Lett. 2018;678:8&#x2013;15. doi: 10.1016/j.neulet.2018.04.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2018.04.053</ArticleId><ArticleId IdType="pmc">PMC5975202</ArticleId><ArticleId IdType="pubmed">29715546</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvatori I., Ferri A., Scaricamazza S., Giovannelli I., Serrano A., Rossi S., D&#x2019;Ambrosi N., Cozzolino M., Giulio A.D., Moreno S., et al. Differential toxicity of TAR DNA-Binding protein 43 isoforms depends on their submitochondrial localization in neuronal cells. J. Neurochem. 2018;146:585&#x2013;597. doi: 10.1111/jnc.14465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14465</ArticleId><ArticleId IdType="pubmed">29779213</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerowitz J., Parker S.J., Vella L.J., Ng D., Price K.A., Liddell J.R., Caragounis A., Li Q.X., Masters C.L., Nonaka T., et al. C-Jun N-terminal kinase controls TDP-43 accumulation in stress granules induced by oxidative stress. Mol. Neurodegener. 2011;6:57. doi: 10.1186/1750-1326-6-57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-6-57</ArticleId><ArticleId IdType="pmc">PMC3162576</ArticleId><ArticleId IdType="pubmed">21819629</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y., Katsuno M., Takagi S., Ishigaki S., Niwa J., Hasegawa M., Tanaka F., Sobue G. Oxidative stress induced by glutathione depletion reproduces pathological modifications of TDP-43 linked to TDP-43 proteinopathies. Neurobiol. Dis. 2012;45:862&#x2013;870. doi: 10.1016/j.nbd.2011.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.12.002</ArticleId><ArticleId IdType="pubmed">22198567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala V., Granado-Serrano A.B., Cacabelos D., Naudi A., Ilieva E.V., Boada J., Caraballo-Miralles V., Llado J., Ferrer I., Pamplona R., et al. Cell stress induces TDP-43 pathological changes associated with ERK1/2 dysfunction: Implications in ALS. Acta Neuropathol. 2011;122:259&#x2013;270. doi: 10.1007/s00401-011-0850-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0850-y</ArticleId><ArticleId IdType="pubmed">21706176</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewey C.M., Cenik B., Sephton C.F., Dries D.R., Mayer P., III, Good S.K., Johnson B.A., Herz J., Yu G. TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor. Mol. Cell. Biol. 2011;31:1098&#x2013;1108. doi: 10.1128/MCB.01279-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01279-10</ArticleId><ArticleId IdType="pmc">PMC3067820</ArticleId><ArticleId IdType="pubmed">21173160</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico E., Factor-Litvak P., Santella R.M., Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2013;65:509&#x2013;527. doi: 10.1016/j.freeradbiomed.2013.06.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.06.029</ArticleId><ArticleId IdType="pmc">PMC3859834</ArticleId><ArticleId IdType="pubmed">23797033</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y.J., Lee L.M., Lai H.L., Chern Y. Aberrant activation of AMP-activated protein kinase contributes to the abnormal distribution of HuR in amyotrophic lateral sclerosis. FEBS Lett. 2015;589:432&#x2013;439. doi: 10.1016/j.febslet.2014.12.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2014.12.029</ArticleId><ArticleId IdType="pubmed">25592834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D., de Assis D.R., Corcia P., Pradat P.F., Blasco H. Metabolomics Biomarkers: A Strategy Toward Therapeutics Improvement in ALS. Front. Neurol. 2018;9:1126. doi: 10.3389/fneur.2018.01126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01126</ArticleId><ArticleId IdType="pmc">PMC6305341</ArticleId><ArticleId IdType="pubmed">30619076</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M., Martin L.J. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum. Mol. Genet. 2010;19:2284&#x2013;2302. doi: 10.1093/hmg/ddq106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq106</ArticleId><ArticleId IdType="pmc">PMC2865380</ArticleId><ArticleId IdType="pubmed">20223753</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Zhang K.Y., Kariawasam R., Bax M., Fifita J.A., Ooi L., Yerbury J.J., Nicholson G.A., Blair I.P. Evaluation of skin fibroblasts from amyotrophic lateral sclerosis patients for the rapid study of pathological features. Neurotox. Res. 2015;28:138&#x2013;146. doi: 10.1007/s12640-015-9532-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-015-9532-1</ArticleId><ArticleId IdType="pubmed">26013250</ArticleId></ArticleIdList></Reference><Reference><Citation>Arima H., Omura T., Hayasaka T., Masaki N., Hanada M., Xu D., Banno T., Kobayashi K., Takeuchi H., Kadomatsu K., et al. Reductions of docosahexaenoic acid-containing phosphatidylcholine levels in the anterior horn of an ALS mouse model. Neuroscience. 2015;297:127&#x2013;136. doi: 10.1016/j.neuroscience.2015.03.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.03.060</ArticleId><ArticleId IdType="pubmed">25841322</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Q., Zhong C. Membrane Aging as the real culprit of alzheimer&#x2019;s disease: Modification of a hypothesis. Neurosci. Bull. 2018;34:369&#x2013;381. doi: 10.1007/s12264-017-0192-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-017-0192-4</ArticleId><ArticleId IdType="pmc">PMC5856718</ArticleId><ArticleId IdType="pubmed">29177767</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagase M., Yamamoto Y., Miyazaki Y., Yoshino H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep. Commun. Free Radic. Res. 2016;21:104&#x2013;112. doi: 10.1179/1351000215Y.0000000026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/1351000215Y.0000000026</ArticleId><ArticleId IdType="pmc">PMC6837462</ArticleId><ArticleId IdType="pubmed">26191780</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>